Clinical trial
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept…
NCT00127842 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00127842 |
|---|---|
| Title | REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) |
| Official title | Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® |
| Lead sponsor | Amgen, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 110 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2005 |
| Completion | Sep 1, 2009 |
| First posted | Aug 9, 2005 |
| Last update posted | Apr 24, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: